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Abstract
Background: Previous studies in patients with rheumatoid arthritis (RA) have shown that switching to tocilizumab
(TCZ) monotherapy (TCZMONO) or combination therapy (TCZCOMBI) with conventional synthetic disease-modifying
anti-rheumatic drugs (csDMARDs) is efficacious in reducing disease activity in patients with inadequate response to
csDMARDs. However, hitherto there is no consensus on whether TCZMONO is as effective as TCZCOMBI. The objective
of this study was therefore to evaluate the efficacy and safety of TCZMONO versus add-on TCZCOMBI and both TCZ
therapies versus continuing the current csDMARD therapy, by performing a systematic review and meta-analyses.
Method: The MEDLINE, EMBASE and CENTRAL databases were searched until February 2016 for relevant randomized
controlled trials (RCTs). We performed meta-analyses of Disease Activity Score in 28 joints (DAS28 < 2.6), American
College of Rheumatology (ACR) 20/50/70 responses, adverse events (AEs) and serious AEs (SAEs) to compare the three
different strategies, whereas a random-effect model was used for pooling relative risks (RR) and 95 % confidence
intervals (CI). In addition, sensitivity analyses were performed for evaluating differences in study duration.
Results: In total, 13 RCTs were included in the meta-analysis, involving 6679 patients. When comparing both TCZ
strategies, a marginally greater proportion of patients achieving DAS28 < 2.6 (RR 1.21; 95 % CI 1.09, 1.36) and ACR50
response (RR 1.14; 95 % CI 1.03, 1.26) was found in favor of the TCZCOMBI strategy. However, the risk of SAEs was also
significantly higher using this strategy (RR 1.40; 95 % CI 1.03, 1.92, p = 0.03). Pooled effect estimates showed statistical
superiority of switching to either TCZ strategy compared to continuing csDMARD therapy.
Conclusions: In the management of active RA, almost similar efficacy can be expected in patients unable to tolerate
csDMARDs, who switch to TCZMONO compared to inadequate responders switching to add-on TCZCOMBI. Although
TCZCOMBI is marginally superior to TCZMONO in achieving DAS28 < 2.6 and ACR50 response, this is at the cost of an
increased risk of SAEs.
Keywords: Rheumatoid arthritis, Tocilizumab, Interleukin-6, Disease-modifying anti-rheumatic drugs, Biological
* Correspondence: x.m.teitsma@umcutrecht.nl
Department of Rheumatology and Clinical Immunology, University Medical
Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, Netherlands
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Teitsma et al. Arthritis Research & Therapy  (2016) 18:211 
DOI 10.1186/s13075-016-1108-9
Background
In the management of rheumatoid arthritis (RA), conven-
tional synthetic disease-modifying anti-rheumatic drugs
(csDMARDs) are recommended as first-line treatment in
DMARD-naïve patients for achieving remission [1–3]. Pa-
tients who have inadequate response to csDMARDs as de-
fined by not achieving the treatment target should receive
add-on therapy with a biological DMARD (bDMARD) if
they have factors linked to poor prognosis (e.g., early joint
damage or seropositivity). However, data obtained from
large cohort studies reveal that approximately one-third of
patients with RA discontinue all csDMARDs and initiate
bDMARD monotherapy, mainly because of intolerance or
noncompliance in taking the csDMARD [4–6]. Adverse
events (AEs) are the main reason for withdrawal (>70 % of
patients), with gastrointestinal symptoms being most fre-
quently observed (>30 % of patients) [6, 7].
For patients in whom continuing csDMARD therapy
is not feasible, it is important to know the effectiveness
and safety of switching to bDMARD monotherapy. To
this day, there is no clear preference as to which biologic
agent (e.g., tumor necrosis factor inhibitors (infliximab,
etanercept, adalimumab, certolizumab pegol, golimu-
mab), rituximab (targeting B-cells), abatacept (targeting
T cells) or tocilizumab (TCZ) (inhibiting interleukin 6
signaling [8]) is preferable if monotherapy must be initi-
ated, because of a lack of head-to-head comparisons. In
ADACTA, [9] a randomized, double-blind, controlled
study, TCZ was shown to be superior to adalimumab in
patients requiring monotherapy and could thus poten-
tially be suitable as first-line biologic therapy. To our
knowledge, this is hitherto the only bDMARD monother-
apy superiority study reported. Several randomized phase
III studies have shown that switching to TCZ monother-
apy or combination therapy is efficacious in achieving
rapid and sustained improvements within patients who do
not achieve the treatment aim with csDMARD therapy
[10–20]. However, there is no consensus as to whether
TCZ as monotherapy is as effective as TCZ combined
with csDMARDs. Although several studies have compared
switching to TCZ monotherapy with add-on combination
therapy, this has not yet been analyzed in meta-analyses.
The objective of this study was to evaluate the efficacy
and safety in patients with RA of TCZ monotherapy ver-
sus add-on TCZ combination therapy, and both TCZ
therapies versus continuing the current csDMARD ther-
apy, by performing a systematic review and meta-analyses.
Methods
Systematic literature search and study selection
A systematic review of the literature was conducted accord-
ing to the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) statement protocol [21].
Relevant publications were identified using MEDLINE,
EMBASE and Cochrane Central Register of Controlled Tri-
als (CENTRAL). The following key search medical subject
heading (MeSH) terms were selected with the help of a li-
brarian: “Rheumatoid Arthritis”[MeSH] OR “Rheumatoid
Arthritis”[tiab] AND (“Tocilizumab”[Suppl. Concept]
OR “Tocilizumab”[tiab] OR “Interleukin-6”[MeSH] OR
“Interleukin-6”[tiab] OR “IL-6”[tiab] OR “IL-6 receptor
inhibitor”[tiab] OR “MRA”[tiab]) AND (“Randomized
controlled trial”[MeSH] OR “randomized controlled
trial”[tiab] OR “Clinical trial”[MeSH] OR “Clinical
trial”[tiab] OR “RCT”[tiab]).
The full search strategy can be found in Additional file
1. All titles and abstracts were independently screened by
two review authors (XMT and ACAM) and studies were
included if: (1) they were RCTs or quasi-RCTs comparing
TCZ 8 mg/kg (TCZMONO) versus TCZ 8 mg/kg +
csDMARD (TCZCOMBI), TCZMONO versus csDMARD or
TCZCOMBI versus csDMARD; (2) patients met the 1987
American College of Rheumatology (ACR) or 2010 ACR/
European League against Rheumatism (EULAR) RA clas-
sification criteria [22, 23] and if they (3) reported ACR 20/
50/70 responses, Disease Activity Score in 28 joints
(DAS28), incidence of AEs and serious AEs (SAEs) within
≤52 weeks. Studies were excluded if: (1) TCZ was com-
pared to another bDMARD; (2) only DMARD-naïve pa-
tients were included; (3) study participants were younger
than 18 years; and (4) articles had not been published in
the English language. If needed, the full text of the article
was obtained for further assessment of eligibility. In
addition, references from relevant articles were also
reviewed for eligible citations. Articles not available were
requested from the authors.
Data extraction and outcome assessment
We abstracted the following data from each study that
was included: design, duration, number of enrolled pa-
tients and baseline characteristics (age, gender, symptom
duration, previous csDMARD and bDMARD use, ery-
throcyte sedimentation rate (ESR), C-reactive protein
(CRP), DAS28 and Health Assessment Questionnaire
score (HAQ). Outcome measurements of DAS28 remis-
sion (<2.6), ACR 20/50/70 responses, AEs and SAEs were
assessed in meta-analyses. The methodological quality of
the studies was independently evaluated by two review au-
thors (XMT and ACAM) using the Cochrane Collabor-
ation recommendations for assessing risk of bias [24].
Information was gathered and assessed on the use of ran-
dom sequence generation, allocation concealment, blind-
ing (of participants, personnel and outcome assessors),
incomplete outcome data, selective reporting and sources
of potential bias. Discrepancies between the two review
authors were resolved by consensus with a third reviewer
(JWGJ).
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Statistical analysis
Meta-analyses were performed for the following treatment-
control combinations: (1) TCZMONO versus TCZCOMBI; (2)
TCZMONO versus csDMARD; and (3) TCZCOMBI versus
csDMARD. Efficacy and safety measures were modeled as
binary outcomes and we used a random-effects model by
employing the Mantel-Haenszel method for pooling relative
risks (RR) and 95 % confidence intervals (CI). During the
study selection we noticed large heterogeneity between stud-
ies; hence a random-effects model was applied [25]. To
analyze the sensitivity of our meta-analyses, we performed
sensitivity analyses by excluding studies not reporting
outcome measures at week 24, to evaluate if differences in
effect sizes between studies occurred due to the variability in
study duration. The I squared statistic (I2) was calculated to
quantify heterogeneity between studies. Furthermore, publi-
cation bias was assessed by visual inspection of asymmetry
in funnel plots, and relative risks were plotted on a logarith-
mic scale [26]. P values <0.05 were considered statistically
significant. Statistical analyses were performed with Review
Manager version 5.3 (Cochrane Collaboration, Oxford, UK).
Results
Literature search and study characteristics
The first search was performed in May 2015 and after re-
moving duplicates we retrieved 583 studies, of which 39
full articles were assessed for eligibility (Fig. 1). Of those
studies, 11 fulfilled the inclusion criteria: Maini et al. 2006
(CHARISMA) [10], Nishimoto et al. 2007 (SAMURAI)
[11], Emery et al. 2008 (RADIATE) [12], Smolen et al.
2008 (OPTION) [14], Genovese et al. 2008 (TOWARD)
[13], Nishimoto et al. 2009 (SATORI) [15], Jones et al.
2010 (AMBITION) [16], Kremer et al. 2011 (LITHE) [17],
Yazici et al. 2012 (ROSE) [18], Weinblatt et al. 2013
(ACT-STAR) [20] and Dougados et al. 2013 (ACT-
RAY) [19]. The search was updated in February 2016
and yielded two additional studies fulfilling the inclu-
sion criteria: Burmester et al. 2015 (FUNCTION) [27]
and Kaneko et al. 2016 (SURPRISE) [28].
Patient demographics and baseline characteristics are
summarized in Table 1. In total 6679 patients were in-
cluded in the meta-analysis (1298 patients treated with
TCZMONO; 3077 patients treated with TCZCOMBI and 2204
patients treated with csDMARD therapy). Demographic
characteristics were comparable between studies with re-
spect to age, gender, ESR, CRP and DAS28. Average symp-
tom duration ranged from 4 to 14 years, except in three
studies [10, 11, 27] of patients with early RA (of duration
≤2 years) only. Furthermore, eight studies [12–16, 18–20]
reported 24-week results for efficacy and safety outcomes,
four studies [11, 17, 27, 28] reported 52-week results and
one study [10] reported outcomes at week 16. For conduct-
ing our meta-analyses, we addressed the corresponding au-
thors of these studies and F Hoffmann-La Roche,
295 records identified in MEDLINE 349 records identified in EMBASE 167 records identified in CENTRAL
585 records identified after duplicates                              
removed
544 records excluded after review of 
the title
41 full articles assessed for eligibility
28 full articles excluded
9 non-randomized
9 not reported on DAS28, AE, SAE
7 conference abstracts
3 not compared TCZ 8 mg/kg mono-
or combination therapy with TCZ
8mg/kg combination therapy or
csDMARDs monotherapy














Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-analyses flow diagram of studies included in the review. ACR American College
of Rheumatology, DAS28 Disease Activity Score in 28 joints, AE adverse event, SAE serious adverse event, TCZ tocilizumab, csDMARDs disease-
modifying anti-rheumatic drugs
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ESR (mm/h) CRP (mg/l) DAS28 HAQ
TCZCOMBI vs. TCZMONO
SURPRISE (2016) TCZCOMBI Open label 52 115 No 0 56 (12) 87 4 (3) 41 (28) 12 (15) 5.1 (1) 1.0 (0.7)
TCZMONO 111 56 (3) 87 4 (3) 45 (30) 18 (26) 5.3 (1.2) 1.0 (0.7)
FUNCTION (2015) TCZCOMBI Double-blind 52 291 No
f 0 50 (14) 79 6 (6)g 53 (30) 26 (30) 6.7 (1.1) 1.5 (0.6)
TCZMONO 292 50 (12) 75 6 (6)
g 51 (28) 25 (32) 6.7(1.0) 1.6 (0.7)
ACT-RAY (2013) TCZCOMBI Open-label,
double-blindc
24 277 No 0 53 (13) 82 8 (8) NR NR 6.3 (1) 1.5 (0.7)
TCZMONO 276 54 (12) 79 8 (8) 6.4 (1) 1.5 (0.6)
ACT-STAR (2013)a TCZCOMBI Open-label 24 360 No 67 54 (12) 78 11 (9) NR 14 (21) 5.5 (1) NR
TCZMONO 163 87 54 (13) 80 14 (10) 19 (33) 6.0 (1)
CHARISMA (2006)b TCZCOMBI Double-blind 16 50 No 14 50 (NR) 78 11 (NR)
c 39 (NR) 24 (NR) 6.5 (NR) NR
TCZMONO 52 50 (NR) 73 9 (NR)
c 39 (NR) 22 (NR) 6.4 (NR)
TCZCOMBI vs. csDMARD
FUNCTION (2015) TCZCOMBI Double-blind 52 291 No 0 50 (14) 79 6 (6)
c 53 (30) 26 (30) 6.7 (1.1) 1.5 (0.6)
csDMARD 289 50 (13) 80 5 (6)c 50 (27) 23 (27) 6.6 (1.0) 1.5 (0.7)
ROSE (2012) TCZCOMBI Double-blind 24 409 No 38 55 (12) 80 9 (9) 46 (24) 17 (21) 6.5 (1) 4.1 (1.7)
h
csDMARD 205 38 56 (12) 84 9 (9) 47 (22) 17 (22) 6.6 (1) 4.0 (2.1)h
LITHE (2011)a TCZCOMBI Double-blind
d 52 398 No 11 53 (12) 82 9 (NR) 46 (25) 23 (26) 6.6 (1) 1.5 (0.6)
csDMARD 393 12 51 (12) 83 9 (NR) 47 (25) 22 (25) 6.5 (1) 1.5 (0.6)
TOWARD (2008) TCZCOMBI Double-blind 24 803 No NS 53 (13) 81 10 (9) 48 (28) 26 (32) 6.7 (1) 1.5 (0.6)
csDMARD 413 54 (13) 84 10 (9) 49 (28) 26 (47) 6.6 (1) 1.5 (0.6)
OPTION (2008)a TCZCOMBI Double-blind 24 205 No 5 51 (12) 85 8 (7) 51 (27) 26 (26) 6.8 (1) 1.6 (0.6)
csDMARD 204 9 51 (12) 78 8 (7) 50 (26) 24 (28) 6.8 (1) 1.5 (0.6)
RADIATE (2008)a TCZCOMBI Double-blind 24 170 No 100 54 (13) 84 13 (9) 49 (28) 28 (33) 6.8 (1) 1.7 (0.6)
csDMARD 158 53 (13) 79 11 (9) 55 (33) 37 (41) 6.8 (1) 1.7 (0.6)
CHARISMA (2006)b TCZCOMBI Double-blind 16 50 No 14 50 (NR) 78 11 (NR)
c 39 (NR) 24 (NR) 6.5 (NR) NR
csDMARD 49 51 (NR) 78 11 (NR)c 43 (NR) 32 (NR) 6.8 (NR)
TCZMONO vs. csDMARD
FUNCTION (2015) TCZMONO Double-blind 52 292 No 0 50 (12) 75 6 (6)
c 51 (28) 25 (32) 6.7(1.0) 1.6 (0.7)
csDMARD 289 50 (13) 80 5 (6)c 50 (27) 23 (27) 6.6 (1.0) 1.5 (0.7)
AMBITION (2010) TCZMONO Double-blind 24 286 No 8 51 (13) 83 6 (8) 50 (28) 30 (33) 6.8 (1) 1.6 (0.7)














Table 1 Study design and baseline characteristics of study participants presented per treatment-control combination (Continued)
SATORI (2009) TCZMONO Double-blind 24 61 No NS 53 (11) 90 9 (8) 52 (28) 30 (20) 6.1 (1) NR
csDMARD 64 51 (12) 75 9 (7) 52 (24) 32 (26) 6.2 (1)
SAMURAI (2007) TCZMONO Open-label
e 52 157 No NS 53 (12) 80 2 (1) 71 (28) 47 (29) 6.5 (1) NR
csDMARD 145 53 (13) 82 2 (1) 71 (25) 49 (29) 6.4 (1)
CHARISMA (2006)b TCZMONO Double-blind 16 52 No 14 50 (NR) 73 9 (NR)
c 39 (NR) 22 (NR) 6.4 (NR) NR
csDMARD 49 51 (NR) 78 11 (NR)c 43 (NR) 32 (NR) 6.8 (NR)
Values are expressed as mean (standard deviation) unless otherwise indicated. aTocilizumab (TCZ) 4 mg + conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) comparator group is excluded in this
overview; bTCZ 2 mg, TCZ 4 mg, TCZ 2 mg + csDMARD and TCZ 4 mg + csDMARD comparator groups were excluded; cTCZ was given open-label, treatment with methotrexate (MTX) was double-blind; dfirst-year ther-
apy was double-blind followed by a second year of open-label therapy; eopen-label for clinical efficacy endpoints, single-blind only for radiographic evaluation; fall patients were MTX-naïve, but only approximately
80 % were entirely csDMARD-naïve; gmonths; hHealth Assessment Questionnaire-physical function (HAQ-PF) score. TCZ tocilizumab, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28 Disease Activity














manufacturer of TCZ and partial owner of the data, to ob-
tain numerical data on the outcome measurements at week
24. For the 52-week studies we were able to obtain the 24-
week data on efficacy outcomes; safety assessments were
not available (except for the LITHE [17]).
Most studies included [10, 12, 14–17, 19, 27, 28] used
methotrexate (MTX) as the csDMARD and folic acid
(≥5 mg/week) was given to all patients to minimize
MTX-related toxicity, except in two studies [15, 19] in
which only 51–81 % of the patients received folic acid.
Folate supplementation was not reported in two other
studies [27, 28]. Before study entry, all patients were on
stable doses of MTX or other csDMARDs for ≥4 weeks
before switching to the TCZMONO or TCZCOMBI strategy,
except in the FUNCTION [27] study in which the major-
ity (81 %) of patients were DMARD-naïve, and the ACT-
STAR [20] study in which patients were on bDMARD
monotherapy before switching to the TCZMONO strategy.
There were also differences between studies in prior anti-
tumor necrosis factor alpha (aTNFα) treatment. In four
studies [10, 14, 16, 17], only a small proportion (5-14 %)
of the patients had received aTNFα medication prior to
inclusion, in contrast to other studies [12, 18, 20] in which
38–100 % of patients had received aTNFα. In several stud-
ies [11, 13, 15], aTNFα treatment was allowed before the
start of the study; however, this proportion was not speci-
fied and in the ACT-RAY [19], FUNCTION [27] and
SURPRISE [28] studies, patients were excluded if they had
previously received aTNFα treatment. In the studies in
which prior aTNFα treatment was allowed, washout pe-
riods were applied before study entry to reduce treatment
effects, except in the ACT-STAR study [20].
The most commonly reported AEs in the studies in-
cluded in our meta-analyses were infections (e.g., skin
and respiratory infections), skin disorders (e.g., rash) and
gastrointestinal symptoms (e.g., nausea). The studies re-
ported an incidence of AEs and SAEs in patients treated
with TCZMONO ranging from 59 to 92 % and from 4 to
18 %, respectively [10, 11, 15, 16, 19, 20]. For TCZCOMBI,
these ranges were 54 to 84 % and 6 to14%, respectively,
[10, 12–14, 18–20] and for csDMARD therapy 47 to
82 % and 3 to 13 %, respectively [10–16, 18].
Efficacy outcomes
DAS28 < 2.6
Forest plots of DAS28 are shown in Fig. 2. In the TCZ
monotherapy and combination strategy, pooled effect es-
timates for achieving remission were significantly higher
(RR 3.95; 95 % CI 2.23, 7.00, p < 0.001 and RR 8.77; 95 % CI
4.10, 18.75, p < 0.001, respectively) compared to csDMARD
therapy. On comparison of the two TCZ strategies, the ef-
fect estimate was significantly higher (RR 1.21; 95 % CI
1.09, 1.36, p < 0.001) for the combination strategy.
ACR20 response
Forest plots of the ACR responses are shown in Additional
file 2. Pooled effect estimates for achieving ACR20 response
were significantly higher for both the TCZMONO (RR 1.68;
95 % CI 1.21, 2.32, p = 0.002) and TCZCOMBI (RR 2.10;
95 % CI 1.48, 2.99, p < 0.001) strategy, when compared to
csDMARD therapy. There was no difference between the
two TCZ strategies (p = 0.11).
ACR50 response
The proportion of ACR50 responders was statistically
higher with both TCZ strategies compared to csDMARD
therapy (TCZMONO: RR 1.87; 95 % CI 1.19, 2.95, p = 0.007
and TCZCOMBI: RR 3.00; 95 % CI 1.80, 4.99, p < 0.001).
Furthermore, patients treated with the add-on TCZCOMBI
strategy achieved an ACR50 response significantly more
often than with the TCZMONO strategy; however, this ef-
fect estimate was relatively small (RR 1.14; 95 % CI 1.03,
1.26, p = 0.008).
ACR70 response
The pooled effect estimates of ACR70 response rates were
significantly higher in patients treated with the TCZMONO
and TCZCOMBI strategy compared to patients treated with
csDMARD therapy (RR 2.11; 95 % CI 1.18, 3.78, p = 0.01
and RR 5.32; 95 % CI 2.31, 12.25, p < 0.001, respectively).
There was no statistically significant difference between
the two TCZ strategies (p = 0.14).
Safety outcomes
Adverse events
For both TCZ strategies, the pooled risk estimates for ex-
periencing one or more AE during treatment was signifi-
cantly higher compared to csDMARD therapy (TCZMONO:
RR 1.08; 95 % CI 1.01, 1.15, p = 0.03; TCZCOMBI: RR 1.12;
95 % CI 1.06, 1.18, p < 0.001, Fig. 3). In the meta-analyses
of TCZMONO versus TCZCOMBI, there was no statistically
significant difference between the strategies (p = 0.17).
SAEs occurred more frequently in the TCZMONO (RR
1.21; 95 % CI 0.87, 1.69) and TCZCOMBI (RR 1.21; 95 %
CI 0.91, 1.60) strategy compared to csDMARD therapy
(Fig. 4). However, this increased risk was not statistically
significant for either TCZ strategy (p = 0.26 and p = 0.19,
respectively). When comparing the incidence of SAEs
with the TCZMONO and TCZCOMBI strategies, the pooled
risk estimate was significantly higher with the combin-
ation strategy (RR 1.40; 95 % CI 1.03, 1.92, p = 0.03).
Publication bias
We found no clear indication of publication bias on vis-
ual inspection of funnel plots (see Additional file 3). The
effect estimates of most studies were within the expected
95 % CI, indicating no clear pattern of bias. However, as-
sessment of publication bias in such a small number of
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studies remains controversial and should be interpreted
with caution [29].
Sensitivity analysis
The pooled effect estimates of the sensitivity analyses
are shown in Table 2; studies were excluded if they did
not report 24-week results. In the efficacy and safety
meta-analysis of TCZCOMBI versus TCZMONO, one [10]
and three studies [10, 27, 28] were excluded, respect-
ively. The effect estimates of the efficacy outcomes
remained relatively unchanged; however, the pooled risk
for SAEs changed from being significant (RR 1.40; 95 %
CI 1.03, 1.92, p = 0.03) to non-significant (RR 1.34; 95 %
CI 0.79, 2.27, p = 0.27), indicating the two TCZ strategies
were equally safe. In the efficacy and safety meta-
analysis of TCZCOMBI versus a csDMARD, one [10] and
two studies [10, 27] were excluded, respectively; the
sensitivity analyses showed greater effect estimates for
DAS28 < 2.6 and ACR20/50/70 responses in favor of the
TCZ strategy; the risk of AEs and SAEs did not change
significantly. In the meta-analysis of TCZMONO versus a
csDMARD, one study [10] was excluded from analysis of
the efficacy outcomes and three studies [10, 11, 27] from
analysis of the safety outcomes; the pooled risk of AEs
changed from being significant (RR 1.08; 95 % CI 1.01,
1.15, p = 0.03) to non-significant (RR 1.13; 95 % CI 0.92,
1.39, p = 0.24) in favor of the TCZ strategy.
Assessment of heterogeneity
A detailed description of the heterogeneity per meta-
analysis is presented in Additional file 4. Heterogeneity
(I2) was the lowest in the TCZCOMBI versus TCZMONO
comparison, indicating minimal differences in effect sizes
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Fig. 2 Forest plots of Disease Activity Score remission (<2.6) assessed in 28 joints (DAS28) comparing tocilizumab combination therapy (TCZCOMBI)
with tocilizumab monotherapy (TCZMONO) (a), TCZCOMBI with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) (b) and
TCZMONO with a csDMARD (c)
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meta-analyses we found substantial heterogeneity (>50 %).
Furthermore, the results of our sensitivity analyses show
that heterogeneity between studies was even slightly in-
creased by excluding studies reporting outcome measures
other than at 24 weeks, which indicates that the between-
study variation in our meta-analyses was not majorly af-
fected by the differences in study duration.
Risk of bias assessment
The risk of bias assessment is shown in Additional file 5.
To appraise the generalizability of our findings, we
assessed the validity of the studies included. Generally,
there was a low risk of selection bias because of ad-
equate allocation concealment, except for the OPTION
study [14]. In this study, the randomization list was pro-
vided by F Hoffmann-La Roche, the manufacturer of
TCZ. The risk of performance and detection bias was
also low because studies were double-blinded, except for
the ACT-RAY, ACT-STAR, SURPRISE and SAMURAI
studies, which were open-label [19, 20, 28] and single-
blinded [11] studies, respectively. Most authors received
consulting and/or speaking fees, honoraria, held a patent
for TCZ, held stock or stock options with the manufac-
turer or were employees of F Hoffmann-La Roche. Also,
except for the SURPRISE study [28], all studies were dir-
ectly supported by F Hoffmann-La Roche or Chugai
Pharmaceutical. Although vested interests do not neces-
sarily lead to bias or impaired study methodology, these
aspects should, however, be weighed in the balance in
coming to a conclusion when determining the efficacy
and safety of TCZ in patients with RA.
Discussion
This is the first meta-analysis comparing the efficacy
and safety of TCZ monotherapy versus TCZ add-on
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Fig. 3 Forest plots of adverse events comparing tocilizumab combination therapy (TCZCOMBI) with tocilizumab monotherapy (TCZMONO) (a),
TCZCOMBI with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) (b) and TCZMONO with a csDMARD (c)
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show that the efficacy of TCZMONO is nearly equivalent
to TCZCOMBI in the management of active RA. Al-
though the effect estimate for achieving DAS28 < 2.6
and ACR50 response was significantly higher with the
TCZCOMBI strategy, this is at the cost of a significant
increase in the risk of SAEs when compared to TCZMONO.
Thus, if patients do not achieve the treatment target after
initiating csDMARD therapy because of intolerance,
switching to TCZMONO is a feasible option in clinical
practice, whereas similar efficacy can be expected com-
pared to inadequate responders to csDMARDs who
switch to add-on TCZCOMBI therapy.
TCZ is the first biologic agent to show comparable ef-
ficacy when used as monotherapy or combination ther-
apy, whereas other biologic agents have consistently
been reported to be significantly less effective when used
as monotherapy [30–33]. To determine if TCZMONO is
also superior to other biologic monotherapies, it is neces-
sary to make direct comparisons in patients who require
this therapy. However, the ADACTA study [9] is hitherto
the only head-to-head randomized trial comparing two
different biologic monotherapies (adalimumab versus
TCZ), whereas TCZ was found to be superior for reducing
signs and symptoms of RA in patients for whom continu-
ation of MTX was discouraged. These findings are en-
dorsed in a network analysis indirectly comparing biologic
monotherapy trials, whereas TCZ has also been associated
with greater efficacy than aTNFα [34]. However, further
research is needed to determine the potential superiority
of TCZ as first-line biologic therapy.
The results of our meta-analyses confirm and extend
findings from previous studies. Although systematic re-
views often do not directly lead to new insights, our re-
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Fig. 4 Forest plots of serious adverse events comparing tocilizumab combination therapy (TCZCOMBI) with tocilizumab monotherapy (TCZMONO) (a),
TCZ COMBI with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) (b) and TCZMONO with a csDMARD (c)
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trials and also has several other advantages. Meta-analyses
are able to examine rare events more adequately by accru-
ing data from several studies and therefore increasing the
likelihood of finding relevant differences. The majority of
the studies included in our systematic review had samples
sizes calculated on the basis of efficacy outcomes, which
are frequently observed, and were thus not powered to de-
tect significant differences in the incidence of less frequent
events such as SAEs.
In this review, five studies [10, 19, 20, 27, 28] were in-
cluded that compared TCZMONO with TCZCOMBI and
none of them demonstrated a significant difference be-
tween the two strategies in the incidence of SAEs. How-
ever, our meta-analyses showed a significantly higher
risk (RR 1.40; 95 % 1.03, 1.92, p = 0.03) of SAEs with the
TCZCOMBI strategy. By pooling effect estimates, meta-
analyses are better able to determine the true efficacy
and safety of therapy compared to individual studies,
and are therefore essential for making future recommen-
dations on the management of RA. Apart from more
adequately estimating the benefit and harms of a ther-
apy, meta-analyses are also able to evaluate the incon-
sistency between studies and quantify treatment effects,
and are invaluable to practitioners, as they summarize
the latest evidence [35, 36].
In our meta-analysis, TCZ was only assessed at a dose
of 8 mg/kg. Previous clinical trials [10, 12, 14, 17, 20, 37]
consistently report superior efficacy of 8 mg/kg compared
to 4 mg/kg in decreasing disease activity and preventing
radiographic evidence of progression. The findings of
these studies were confirmed in several systematic re-
views, whereas meta-analyses have shown significantly
greater efficacy with the 8-mg/kg dose [38, 39]. In another
review performed by Campbell et al. [40], the risk of AEs
was not significantly different between the two different
doses, which supports the superior dose–response rela-
tionship of the higher dose. TCZ inhibits the binding of
IL-6 to its receptor, which has its direct effects on acute
phase reactants (APR) such as CRP and ESR. Although
reduction in APR was sustained in patients treated with
Table 2 Efficacy and safety outcomes of tocilizumab 8 mg/kg monotherapy and combination therapy comprising tocilizumab and a
conventional synthetic disease modifying anti-rheumatic drug
Meta-analysis Sensitivity analysesa
Outcome measures RR 95 % CI P RR 95 % CI P
TCZCOMBI vs. TCZMONO
DAS28 < 2.6 1.21 1.09, 1.36 <0.001 1.20 1.07, 1.34 0.002
ACR20 1.05 0.99, 1.12 0.11 1.05 0.98, 1.11 0.17
ACR50 1.14 1.03, 1.26 0.008 1.13 1.02, 1.25 0.02
ACR70 1.19 0.94, 1.51 0.14 1.12 0.95, 1.33 0.19
AEs 1.08 0.97, 1.21 0.17 1.09 0.86, 1.38 0.48
SAEs 1.40 1.03, 1.92 0.03 1.34 0.79, 2.27 0.27
TCZCOMBI vs. csDMARD
DAS28 < 2.6 8.77 4.10, 18.75 <0.001 10.39 4.38, 24.65 <0.001
ACR20 2.10 1.48, 2.99 <0.001 2.15 1.45, 3.19 <0.001
ACR50 3.00 1.80, 4.99 <0.001 3.24 1.82, 5.78 <0.001
ACR70 5.32 2.31, 12.25 <0.001 6.23 2.29, 16.93 <0.001
AEs 1.12 1.06, 1.18 <0.001 1.14 1.07, 1.20 <0.001
SAEs 1.21 0.91, 1.60 0.19 1.13 0.80, 1.60 0.48
TCZMONO vs. csDMARD
DAS28 < 2.6 3.95 2.23, 7.00 <0.001 4.50 2.34, 8.64 <0.001
ACR20 1.68 1.21, 2.32 0.002 1.71 1.18, 2.48 0.005
ACR50 1.87 1.19, 2.95 0.007 2.01 1.18, 3.42 0.01
ACR70 2.11 1.18, 3.78 0.01 2.49 1.29, 4.81 0.007
AEs 1.08 1.01, 1.15 0.03 1.13 0.92, 1.39 0.24
SAEs 1.21 0.87, 1.69 0.26 1.37 0.64, 2.93 0.42
aThe CHARISMA study was excluded from all meta-analyses; the FUNCTION study was excluded from all meta-analyses of safety outcomes (adverse events (AEs)
and serious AEs (SAEs)); the SAMURAI study was excluded from meta-analyses of the safety of tocilizumab monotherapy (TCZMONO) vs. a conventional synthetic
disease-modifying anti-rheumatic drug (csDMARD); the SURPRISE study was excluded (from meta-analyses of the safety of tocilizumab combination therapy
(TCZCOMBI) vs. TCZMONO.RR relative risk, CI confidence interval, DAS28 Disease Activity Score in 28 joints, ACR American college of Rheumatology, AEs adverse
events, SAEs serious AEs
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8 mg/kg, these decreases were not maintained with
4 mg/kg, possibly indicating less sufficient targeting of
the IL-6 pathway and therefore resulting in less efficacy
[14, 17, 41].
In this review we also evaluated the efficacy and safety
of both TCZ strategies versus csDMARD therapy. Accord-
ing to current guidelines, newly diagnosed patients with
RA should receive csDMARD therapy as the first-line
treatment, and in the case of inefficacy or intolerability,
switch to or add a biologic DMARD. Before making as-
sumptions as to whether TCZMONO or TCZCOMBI would
be adequate to decrease symptoms in patients not
achieving the treatment target with csDMARD therapy
alone, it is necessary to compare the efficacy of both
these strategies with the standard of care. Although a
proportion of patients did not initially achieve remis-
sion with csDMARD therapy, this does not necessary
mean that this therapy was not effective at all. Thus,
the efficacy of TCZMONO could be not significantly bet-
ter than that of the csDMARD therapy in these patients
who are more difficult to treat, and then, switching to
TCZMONO would thus not be a good option for patients
who do not respond to csDMARDs.
Although this is the first meta-analysis comparing
TCZMONO with csDMARD therapy, TCZCOMBI has
already been compared to csDMARD therapy in previ-
ous meta-analyses [38–40]. Our meta-analysis of this
treatment-control combination differs to these studies
because: (1) several new large RCTs have been pub-
lished; (2) 24-week results were obtained from studies
with longer follow up; and (3) we performed sensitivity
analyses to assess the heterogeneity between studies.
The results of our meta-analyses show that switching to
TCZMONO and TCZCOMBI therapy is superior to con-
tinuing csDMARD therapy alone in patients with active
RA. However, the treatment effect of TCZ is likely to
be enhanced by the study design of the RCTs, because
in studies with a csDMARD comparator group [10–18],
patients were already on this therapy prior to inclusion,
except in the FUNCTION study [27], whereas 81 % of
the patients were DMARD-naïve.
TCZ, as monotherapy or combination therapy, has also
shown to be effective as first-line therapy in newly diag-
nosed treatment-naïve patients with RA. In U-Act-Early
[42], a recently published randomized, multicenter, three-
parallel-arm, double-blind, treat-to-target study, DMARD-
naïve patients were allocated to start on TCZMONO,
TCZCOMBI or MTX therapy. Both TCZ strategies were
found to be more effective in achieving sustained remis-
sion (TCZCOMBI 86 %, TCZMONO 83 %) compared to
MTX (44 %, p < 0.001). This study endorses the immediate
initiation of TCZ in early RA, with or without MTX, when
used in a treat-to-target approach, including tapering of
medication when remission is achieved.
Several weaknesses are apparent in this meta-
analyses, which will be addressed. First, studies in-
cluded in our review were heterogeneous in respect to
csDMARD therapy. The majority used MTX monother-
apy [10, 12, 14–17, 19] as control therapy; however, in
four studies [11, 13, 18, 20] several csDMARDs were per-
mitted. Furthermore, MTX was given at a lower dose in
Japanese studies [11, 15] compared to studies performed
in Caucasian populations [10, 12, 14, 16, 17, 19] because
of the different health regulations. Second, the treatment
efficacy of TCZ as assessed using the DAS28 should be
interpreted with caution because of the prominent effect
of IL-6 inhibition by TCZ on APR, which can lead to ex-
aggerated response rates when compared to csDMARD or
other bDMARD therapies. Thus, we also used ACR re-
sponse criteria for evaluating efficacy, which yielded
similar findings when compared to DAS28, endorsing the
superiority of switching to TCZMONO or TCZCOMBI ther-
apy compared to continuing csDMARD therapy. Third,
studies also differed with respect to study duration. Sensi-
tivity analyses were performed to assess whether studies
with follow up shorter or longer than 24 weeks reported
systematically different treatment effects. In general, the
effect estimates and the between-study variation did not
change significantly and thus, does not change our pre-
vious conclusions. However, it may indicate that other fac-
tors such as demographic characteristics (e.g., early versus
established RA) and prior DMARD use (e.g., MTX-naïve
versus non-naïve patients) probably contribute more to
the heterogeneity. Unfortunately because of the limited
number of studies included in this review, we were not
able to explore these potential sources of between-study
variability.
Conclusions
In conclusion, in the management of active RA, switch-
ing to TCZMONO is a good option for patients who can-
not tolerate csDMARDs, whereas similar efficacy can
be expected compared to TCZCOMBI therapy. Although
TCZCOMBI is marginally superior to TCZMONO in terms
of achieving DAS28 < 2.6 and ACR50 response, this is at
the cost of a significantly increased risk of SAEs. TCZ is
the first biologic agent to show comparable efficacy when
used as monotherapy or combination therapy.
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